| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.2 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.07 | 0.2 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.097 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |